TG Therapeutics, Inc. TGTX
At closeNov 6, 2026, 7:45 PM EST
After hours · Nov 6, 7:45 PM ET
- YTD
- +100.69%
- 1 year
- +79.87%
- Market cap
- 9.16B
- Revenue (ttm)
- 799.54M
- Profit margin
- 55.22%
- EPS (ttm)
- 2.75
- Shares out
- 153.07M
- P/E ratio
- 21.75
- Forward P/E
- 22.09
- YTD return
- +100.69%
- 1-year return
- +79.87%
- Volume
- 2.31M
- Avg volume
- 1.80M
- Open
- 57.99
- Previous close
- 57.98
- Day's range
- 57.59 – 60.82
- 52-week range
- 26.94 – 61.63
- Beta
- 1.81
- Analysts
- Strong Buy
- Price target
- 69.71 (+16.5%)
- Earnings date
- Nov 9, 2026
1M +6.88 (+12.99%)
Key statistics
- Enterprise value
- 8.43B
- PEG ratio
- 1.61
- Price / sales
- 11.45
- Price / book
- 14.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 70.30%
- Free cash flow
- 59.13M
- Total cash
- 552.25M
- Total debt
- 754.44M
- Return on equity
- 100.28%
- Short % of float
- 27.94%
- 50-day average
- 55.72
- 200-day average
- 44.39
Analyst view
Consensus: strong buy
- Target (low)
- 21.00
- Target (mean)
- 69.71
- Target (high)
- 86.00
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell1
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate 0.2575.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | 0.3668 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 0.3057 | 0.05 | -0.26 | -83.64% |
| May 6, 2026 | Mar 31, 2026 | 0.23 | 0.14 | -0.09 | -39.13% |
| Feb 26, 2026 | Dec 31, 2025 | 0.35 | 0.14 | -0.21 | -60.00% |
| Nov 3, 2025 | Sep 30, 2025 | 0.24 | 2.43 | +2.19 | +912.50% |
| Aug 4, 2025 | Jun 30, 2025 | 0.32 | 0.17 | -0.15 | -46.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Jul 27, 2026 | B. Riley Securities | main | Buy | Buy |
| Jul 13, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 7, 2026 | B of A Securities | main | Underperform | Underperform |
| Jul 6, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tgtherapeutics.com
News
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates 
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update 
TG Therapeutics' Initial Data From Its Phase 1 Trial Of Azercabtagene Zapreleucel In Patients With Progressive Multiple Sclerosis Demonstrates 89% Of Evaluable Participants Had Stable Or Improved Disability Scores At Day 90 
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach 
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $78 Price Target 
MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday - JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72
10 Health Care Stocks With Whale Alerts In Today’s Session 
Top 3 Health Care Stocks That May Collapse This Quarter 
Caseys General Stores Upbeat Q4 Earnings, Joins Applied Optoelectronics, Clover Health Investments And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on TGTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHARNEY LAURENCE NEIL | Director | Sale | Sep 9, 2026 | 168,640 |
| ECHELARD YANN | Director | Sale | Nov 23, 2025 | 223,816 |
| HOBERMAN KENNETH | Director | Stock Award(Grant) | Jun 11, 2025 | 279,653 |
| HUME DANIEL | Director | Stock Award(Grant) | Jun 11, 2025 | 192,748 |
| LONIAL SAGAR | Director | Sale | Sep 10, 2025 | 94,061 |
| POWER SEAN A | Chief Financial Officer | Stock Award(Grant) | Jan 7, 2026 | 798,111 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.41% | 22,050,045 | 1.32B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.20% | 7,963,266 | 476.40M | Jun 29, 2026 |
| State Street Corporation | 5.09% | 7,786,471 | 465.83M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.02% | 6,149,403 | 367.89M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.38% | 3,642,216 | 217.90M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 2.22% | 3,400,808 | 203.45M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.52% | 8,449,942 | 505.52M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.86% | 4,377,027 | 261.86M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.46% | 3,765,888 | 225.29M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.06% | 3,160,785 | 189.09M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.77% | 2,703,952 | 161.76M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.19% | 1,820,899 | 108.94M | Jun 29, 2026 |